Oral cancer, cigarette smoke and mitochondrial 18kDa translocator protein (TSPO) - In vitro, in vivo, salivary analysis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 5, 2010, Pages 454-461

  Nagler, Rafael ^a   Ben Izhak, Ofer ^a   Savulescu, Dana ^a   Krayzler, Ella ^a   Akrish, Sharon ^a   Leschiner, Svetlana ^a   Otradnov, Irina ^a   Zeno, Sivan ^a   Veenman, Leo ^a   Gavish, Moshe ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cigarette smoke; Oral cancer; Prognosis; Saliva; TSPO

Indexed keywords

CARRIER PROTEIN; PROTEIN TSPO; UNCLASSIFIED DRUG;

AGED; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER SURVIVAL; CELL VIABILITY; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUTH CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BINDING; SALIVA ANALYSIS; SURVIVAL RATE;

AGED; CASE-CONTROL STUDIES; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MOUTH NEOPLASMS; RECEPTORS, GABA; S-PHASE KINASE-ASSOCIATED PROTEINS; SALIVA; SMOKING; TUMOR CELLS, CULTURED;

EID: 77950369069     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.01.008     Document Type: Article

References (50)

1. Reznick A.Z., Hershkovich O., Nagler R.M. Saliva - a pivotal player in the pathogenesis of oropharyngeal cancer. Br. J. Cancer 2004, 91:111-118.
2. Kantola S., Parikka M., Jokinen K., Hyrynkangs K., Soini Y., Alho O.P., Salo T. Prognostic factors in tongue cancer - relative importance of demographic, clinical and histopathological factors. Br. J. Cancer 2000, 83:614-619.
3. Myers J.N., Elkins T., Roberts D., Byers R.M. Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. Otolaryngol. Head Neck Surg. 2000, 122:44-51.
4. Ribeiro K.C., Kowalski L.P., Latorre M.R. Impact of comorbidity, symptoms, and patients' characteristics on the prognosis of oral carcinomas. Arch. Otolaryngol. Head Neck Surg. 2000, 126:1079-1085.
5. Braestrup C., Squires R.F. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc. Natl. Acad. Sci. USA 1977, 74:3805-3809.
6. Gavish M., Bachman I., Shoukrun R., Katz Y., Veenman L., Weisinger G., Weizman A. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev. 1999, 51:629-650.
7. Veenman L., Gavish M. The peripheral-type benzodiazepine receptor and the cardiovascular system: implications for drug development. Pharmacol. Therap. 2006, 110:503-524.
8. Katz Y., Ben-Baruch G., Kloog Y., Menczer J., Gavish M. Increased density of peripheral benzodiazepine-binding sites in ovarian carcinomas as compared with benign ovarian tumours and normal ovaries. Clin. Sci. (Lond.) 1990, 78:155-158.
9. Katz Y., Eitan A., Gavish M. Increase in peripheral benzodiazepine binding sites in colonic adenocarcinoma. Oncology 1990, 47:139-142.
10. Maaser K., Höpfner M., Jansen A., Weisinger G., Gavish M., Kozikowski A.P., Weizman A., Carayon P., Riecken E.O., Zeitz M., Scherübl H. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br. J. Cancer 2001, 85:1771-1780.
11. Maaser K., Grabowski P., Sutter A.P., Krahn A., Heine B., Stein H., Buhr H., Zeitz M., Scherübl H. Up-regulation of the peripheral benzodiazepine receptor during human colorectal carcinogenesis and tumor spread. Clin. Cancer Res. 2005, 11:1751-1756.
12. Han Z., Slack R.S., Li W., Papadopoulos V. Expression of peripheral benzodiazepine receptor (PBR) in human tumors: relationship to breast, colorectal, and prostate tumor progression. J. Recept. Signal Transduct. Res. 2003, 23:225-238.
13. Galiègue S., Casellas P., Kramar A., Tinel N., Simony-Lafontaine J. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin. Cancer Res. 2004, 10:2058-2064.
14. Veenman L., Levin E., Weisinger G., Leschiner S., Spanier I., Snyder S.H., Weizman A., Gavish M. Peripheral-type benzodiazepine receptor density and in vitro tumorigenicity of glioma cell lines. Biochem. Pharmacol. 2004, 68:689-698.
15. Weisinger G., Kelly-Hershkovitz E., Veenman L., Spanier I., Leschiner S., Gavish M. Peripheral benzodiazepine receptor antisense knockout increases tumorigenicity of MA-10 Leydig cells in vivo and in vitro. Biochemistry 2004, 43:12315-12321.
16. Levin E., Premkumar A., Veenman L., Kugler W., Leschiner S., Spanier I., Weisinger G., Lakomek M., Weizman A., Snyder S.H., Pasternak G.W., Gavish M. The peripheral-type benzodiazepine receptor and tumorigenicity: isoquinoline binding protein (IBP) antisense knockdown in the C6 glioma cell line. Biochemistry 2005, 44:9924-9935.
17. Kugler W., Veenman L., Shandalov Y., Leschiner S., Spanier I., Lakomek M., Gavish M. Ligands of the mitochondrial 18kDa translocator protein attenuate apoptosis of human glioblastoma cells exposed to erucylphosphohomocholine. Cell. Oncol. 2008, 30:435-450.
18. Shoukrun R., Veenman L., Shandalov Y., Leschiner S., Spanier I., Karry R., Katz Y., Weisinger G., Weizman A., Gavish M. The 18-kDa translocator protein, formerly known as the peripheral-type benzodiazepine receptor, confers proapoptotic and antineoplastic effects in a human colorectal cancer cell line. Pharmacogenet. Genomics 2008, 18:977-988.
19. Veenman L., Shandalov Y., Gavish M. VDAC activation by the 18kDa translocator protein (TSPO), implications for apoptosis. J. Bioenerg. Biomembr. 2008, 40:199-205.
20. Zeno S., Zaaroor M., Leschiner S., Veenman L., Gavish M. CoCl(2) induces apoptosis via the 18kDa translocator protein in U118MG human glioblastoma cells. Biochemistry 2009, 48:4652-4661.
21. Ben-Izhak O., Akrish S., Gan S., Nagler R.M. P27 and salivary cancer. Cancer Immunol. Immunother. 2009, 58:469-473.
22. Shpitzer T., Bahar G., Feinmesser R., Nagler R.M. A comprehensive salivary analysis for oral cancer diagnosis. J. Cancer Res. Clin. Oncol. 2007, 133(9):613-617.
23. Reznick A.Z., Klein I., Eiserich J.P., Cross C.E., Nagler R.M. Inhibition of oral peroxidase activity by cigarette smoke: in vivo and in vitro studies. Free Radic. Biol. Med. 2003, 34:377-384.
24. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
25. Awad M., Gavish M. Binding of [3H]Ro5-4864 and [3H]PK 11195 to cerebral cortex and peripheral tissues of various species: species differences and heterogeneity in peripheral Benzodiazepine binding sites. J. Neurochem. 1987, 49:1407-1414.
26. Kelly-Hershkovitz E., Weizman R., Spanier I., Leschiner S., Lahav M., Weisinger G., Gavish M. Effects of peripheral-type benzodiazepine receptor antisense knockout on MA-10 Leydig cell proliferation and steroidogenesis. J. Biol. Chem. 1998, 273:5478-5483.
27. Veenman L., Leschiner S., Spanier I., Weisinger G., Weizman A., Gavish M. PK 11195 attenuates kainic acid-induced seizures and alterations in peripheral-type benzodiazepine receptor (PBR) protein components in the rat brain. J. Neurochem. 2002, 80:917-927.
28. Nagler R.M., Lischinsky S., Diamond E., Klein I., Reznick A.Z. New insights into salivary lactate dehydrogenase of human subjects. J. Lab. Clin. Med. 2001, 137:363-369.
29. Bahar G., Feinmesser R., Shpitzer T., Popovtzer A., Nagler R.M. Salivary analysis in oral cancer patients: DNA and protein oxidation, reactive nitrogen species, and antioxidant profile. Cancer 2007, 109(1):54-59.
30. Nagler R., Bahar G., Shpitzer T., Feinmesser R. Concomitant analysis of salivary tumor markers - a new diagnostic tool for oral cancer. Clin. Cancer Res. 2006, 12(13):3979-3984.
31. Hasnis E., Bar-Shai M., Burbea Z., Reznick A.Z. Cigarette smoke-induced NF-kappaB activation in human lymphocytes: the effect of low and high exposure to gas phase of cigarette smoke. J. Physiol. Pharmacol. 2007, 58(Suppl 5 (Pt 1)):263-274.
32. Hasnis E., Bar-Shai M., Burbea Z., Reznick A.Z. Mechanisms underlying cigarette smoke-induced NF-kappaB activation in human lymphocytes: the role of reactive nitrogen species. J. Physiol. Pharmacol. 2007, 58(Suppl 5 (Pt 1)):275-287.
33. Bar-Shai M., Hasnis E., Wiener-Megnazi Z., Reznick A.Z. The role of reactive nitrogen species and cigarette smoke in activation of transcription factor NF-kappaB and implication to inflammatory processes. J. Physiol. Pharmacol. 2006, 57(Suppl 4):39-44.
34. Ben Izhak O., Kablan F., Laster Z., Nagler R.M. Oropharyngeal cancer pathogenesis: ubiquitin proteolytic, apoptotic and epidermal growth factor related pathways act in concert - first report. Oral Oncol. 2005, 41:851-860.
35. Chelli B., Lena A., Vanacore R., Pozzo E.D., Costa B., Rossi L., Salvetti A., Scatena F., Ceruti S., Abbracchio M.P., Gremigni V., Martini C. Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. Biochem. Pharmacol. 2004, 68:125-134.
36. R. Nagler, D. Savulescu, E. Krayzler, S. Leschiner, L. Veenman, M. Gavish, Cigarette smoke decreases salivary 18kDa Translocator Protein binding affinity - in association with oxidative stress, Current Medical Chemistry (in press).
37. L. Veenman, J. Alten, K. Linnemannstöns, Y. Shandalov, M. Lakomek, M. Gavish, W. Kugler, Potential involvement of F0F1-ATP(synth)ase and reactive oxygen species in apoptosis induction by the antineoplastic agent erucylphosphohomocholine in glioblastoma cell lines: A mechanism for induction of apoptosis via the 18 kDa mitochondrial translocator protein. (2010) [Electronic publication ahead of print].
38. L. Veenman, A. Weizman, G. Weisinger, M. Gavish, in press. Expression and functions of the 18kDa Mitochondrial Translocator Protein (TSPO) in Health and Disease. Targeted Drug Delivery in Cancer Therapeutics.
39. Veenman L., Papadopoulos V., Gavish M. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr. Pharm. Des. 2007, 13:2385-2405.
40. Pietsch E.C., Humbey O., Murphy M.E. Polymorphisms in the p53 pathway. Oncogene 2006, 25:1602-1611.
41. Li W., Hardwick M.J., Rosenthal D., Culty M., Papadopoulos V. Peripheral-type benzodiazepine receptor overexpression and knockdown in human breast cancer cells indicate its prominent role in tumor cell proliferation. Biochem. Pharmacol. 2007, 15:491-503.
42. Panickar K.S., Jayakumar A.R., Rama Rao K.V., Norenberg M.D. Downregulation of the 18-kDa translocator protein: effects on the ammonia-induced mitochondrial permeability transition and cell swelling in cultured astrocytes. Glia 2007, 55:1720-1727.
43. Chelli B., Salvetti A., Da Pozzo E., Rechichi M., Spinetti F., Rossi L., Costa B., Lena A., Rainaldi G., Scatena F., Vanacore R., Gremigni V., Martini C. PK 11195 differentially affects cell survival in human wild-type and 18kDa translocator protein-silenced ADF astrocytoma cells. J. Cell. Biochem. 2008, 105:712-723.
44. Rechichi M., Salvetti A., Chelli B., Costa B., Da Pozzo E., Spinetti F., Lena A., Evangelista M., Rainaldi G., Martini C., Gremigni V., Rossi L. TSPO over-expression increases motility, transmigration and proliferation properties of C6 rat glioma cells. Biochim. Biophys. Acta 2008, 1782:118-125.
45. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapère J.J., Lindemann P., Norenberg M.D., Nutt D., Weizman A., Zhang M.R., Gavish M. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 2006, 27:402-409.
46. Sasco A.J., Secretan M.B., Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004, 45(Suppl 2):S3-S9.
47. Delavoie F., Li H., Hardwick M., Robert J., Giatzakis C., Peranzi G., Maccario J., Lacapere J., Papadopoulos V. In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry 2003, 42:4506-4519.
48. Miyakawa A., Wang X.L., Nakanishi H., Imai F.L., Shiiba M., Miya T., Imai Y., Tanzawa H. Allelic loss on chromosome 22 in oral cancer: possibility of the existence of a tumor suppressor gene on 22q13. Int. J. Oncol. 1998, 13:705-709.
49. Reis P.P., Rogatto S.R., Kowalski L.P., Nishimoto I.N., Montovani J.C., Corpus G., Squire J.A., Kamel-Reid S. Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. Oncogene 2002, 21:6480-6487.
50. Dos Reis P.P., Poli-Frederico R.C., dos Santos R.M., Nishimoto I.N., Kowalski L.P., Rogatto S.R. Distinct regions of loss of heterozygosity on 22q in different sites of head and neck squamous cell carcinomas. Med. Sci. Monit. 2002, 8:BR89-BR94.